Dataset: Expression data from esophageal squamous cell carcinomas and normal esophageal epithelia
Preoperative chemoradiotherapy (CRT) followed by surgery has been proved to improve esophageal squamous cell carcinoma (ESCC) patients’...
Preoperative chemoradiotherapy (CRT) followed by surgery has been proved to improve esophageal squamous cell carcinoma (ESCC) patients’ survival in comparison with surgery alone. However, the outcomes of CRT are heterogeneous, and no clinical or pathological method could predict CRT response. We aim to identify mRNA markers for ESCC CRT-response prediction through gene expression analyses. Gene expression analyses were performed on pretreatment cancer biopsies from 28 ESCCs who received neoadjuvant CRT and surgery and 10 normal esophageal epithelia using Affymetrix U133 Plus 2.0 arrays.
- Species:
- human
- Samples:
- 38
- Source:
- E-GEOD-45670
- Updated:
- Dec.12, 2014
- Registered:
- Sep.21, 2014
Factors:
(via ArrayExpress)
Sample | PATHOLOGICAL RESPONSE TO CRP | AGE | TUMOR STAGE | ORGANISM PART | SEX |
---|---|---|---|---|---|
GSM1111662 | nan | 69 | T3N1M0 | normal esophageal epithelium | male |
GSM1111663 | nan | 59 | T2N1M0 | normal esophageal epithelium | male |
GSM1111664 | nan | 50 | T2N1M0 | normal esophageal epithelium | female |
GSM1111665 | nan | 65 | T2N1M0 | normal esophageal epithelium | male |
GSM1111662 | nan | 69 | T3N1M0 | normal esophageal epithelium | male |
GSM1111667 | nan | 53 | T3N1M0 | normal esophageal epithelium | female |
GSM1111668 | nan | 65 | T3N1M0 | normal esophageal epithelium | female |
GSM1111669 | nan | 49 | T3N1M0 | normal esophageal epithelium | male |
GSM1111670 | nan | 65 | T3N1M0 | normal esophageal epithelium | male |
GSM111167 | nan | 63 | T3N1M0 | normal esophageal epithelium | male |
GSM1111672 | not pathological complete response | 61 | T3N1M0 | esophageal squamous cell carcinoma (ESCC) | male |
GSM1111673 | not pathological complete response | 43 | T3N1M0 | esophageal squamous cell carcinoma (ESCC) | male |
GSM1111674 | not pathological complete response | 59 | T3N1M0 | esophageal squamous cell carcinoma (ESCC) | male |
GSM1111675 | not pathological complete response | 50 | T3N1M0 | esophageal squamous cell carcinoma (ESCC) | male |
GSM1111674 | not pathological complete response | 59 | T3N1M0 | esophageal squamous cell carcinoma (ESCC) | male |
GSM1111677 | not pathological complete response | 55 | T3N1M0 | esophageal squamous cell carcinoma (ESCC) | male |
GSM1111678 | not pathological complete response | 54 | T2N1M0 | esophageal squamous cell carcinoma (ESCC) | male |
GSM1111679 | not pathological complete response | 53 | T3N1M0 | esophageal squamous cell carcinoma (ESCC) | male |
GSM1111680 | not pathological complete response | 57 | T2N1M0 | esophageal squamous cell carcinoma (ESCC) | female |
GSM111168 | not pathological complete response | 53 | T2N1M0 | esophageal squamous cell carcinoma (ESCC) | male |
GSM1111682 | not pathological complete response | 60 | T2N1M0 | esophageal squamous cell carcinoma (ESCC) | male |
GSM1111683 | not pathological complete response | 54 | T3N1M0 | esophageal squamous cell carcinoma (ESCC) | male |
GSM1111683 | not pathological complete response | 54 | T3N1M0 | esophageal squamous cell carcinoma (ESCC) | male |
GSM1111685 | not pathological complete response | 69 | T3N1M0 | esophageal squamous cell carcinoma (ESCC) | male |
GSM1111679 | not pathological complete response | 53 | T3N1M0 | esophageal squamous cell carcinoma (ESCC) | male |
GSM1111679 | not pathological complete response | 53 | T3N1M0 | esophageal squamous cell carcinoma (ESCC) | male |
GSM1111674 | not pathological complete response | 59 | T3N1M0 | esophageal squamous cell carcinoma (ESCC) | male |
GSM1111689 | pathological complete response | 62 | T3N1M0 | esophageal squamous cell carcinoma (ESCC) | male |
GSM1111690 | pathological complete response | 48 | T3N1M0 | esophageal squamous cell carcinoma (ESCC) | male |
GSM111169 | pathological complete response | 56 | T3N1M0 | esophageal squamous cell carcinoma (ESCC) | female |
GSM1111692 | pathological complete response | 49 | T2N1M0 | esophageal squamous cell carcinoma (ESCC) | male |
GSM1111693 | pathological complete response | 59 | T2N1M0 | esophageal squamous cell carcinoma (ESCC) | female |
GSM1111694 | pathological complete response | 46 | T3N1M0 | esophageal squamous cell carcinoma (ESCC) | male |
GSM1111695 | pathological complete response | 64 | T3N1M0 | esophageal squamous cell carcinoma (ESCC) | male |
GSM1111696 | pathological complete response | 59 | T3N1M0 | esophageal squamous cell carcinoma (ESCC) | male |
GSM1111697 | pathological complete response | 65 | T3N1M0 | esophageal squamous cell carcinoma (ESCC) | male |
GSM1111698 | pathological complete response | 63 | T2N1M0 | esophageal squamous cell carcinoma (ESCC) | male |
GSM1111699 | pathological complete response | 61 | T2N1M0 | esophageal squamous cell carcinoma (ESCC) | male |